Abstract
Gene therapy is a promising strategy to deliver growth factors of interest locally in a sustained fashion and has the potential to overcome barriers to using recombinant protein therapy such as sustainability and cost. Recent studies demonstrate the safety and efficacy of non-viral delivery of plasmid DNA (pDNA) encoding a single growth factor to enhance bone healing. This pilot study is aimed at testing a non-viral gene delivery system that can deliver two different plasmids encoding two different growth factors. Polyethylenimine (PEI), a cationic polymer, was utilized as a gene delivery vector and collagen scaffold was used as a carrier to deliver the PEI-pDNA complexes encoding platelet derived growth factor B (PDGF-B) and/or vascular endothelial growth factor (VEGF). Calvarial defects in rats were implanted with scaffolds containing PEI-pPDGF-B complexes, PEI-pVEGF complexes or containing both PEIpPDGF- B and PEI-pVEGF complexes in a 1:1 ratio of plasmids. The results indicated that bone regeneration as measured using micro-CT and histological assessments was inferior in groups treated with PEI-(pPDGF-B + pVEGF) complexes, compared to defects treated with PEI-pPDGF-B complexes. This pilot study that explores the feasibility and efficacy of combinatorial non-viral gene delivery system for bone regeneration appears to provide a rationale for investigation of sequential delivery of growth factors at specific time points during the healing phases and this will be explored further in future studies.
Keywords: Bone regeneration, collagen scaffolds, non-viral gene delivery, PDGF-B, polyethylenimine, VEGF.
Current Pharmaceutical Biotechnology
Title:A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects
Volume: 16 Issue: 7
Author(s): Sheetal R. D'Mello, Satheesh Elangovan, Liu Hong, Ryan D. Ross, D. Rick Sumner and Aliasger K. Salem
Affiliation:
Keywords: Bone regeneration, collagen scaffolds, non-viral gene delivery, PDGF-B, polyethylenimine, VEGF.
Abstract: Gene therapy is a promising strategy to deliver growth factors of interest locally in a sustained fashion and has the potential to overcome barriers to using recombinant protein therapy such as sustainability and cost. Recent studies demonstrate the safety and efficacy of non-viral delivery of plasmid DNA (pDNA) encoding a single growth factor to enhance bone healing. This pilot study is aimed at testing a non-viral gene delivery system that can deliver two different plasmids encoding two different growth factors. Polyethylenimine (PEI), a cationic polymer, was utilized as a gene delivery vector and collagen scaffold was used as a carrier to deliver the PEI-pDNA complexes encoding platelet derived growth factor B (PDGF-B) and/or vascular endothelial growth factor (VEGF). Calvarial defects in rats were implanted with scaffolds containing PEI-pPDGF-B complexes, PEI-pVEGF complexes or containing both PEIpPDGF- B and PEI-pVEGF complexes in a 1:1 ratio of plasmids. The results indicated that bone regeneration as measured using micro-CT and histological assessments was inferior in groups treated with PEI-(pPDGF-B + pVEGF) complexes, compared to defects treated with PEI-pPDGF-B complexes. This pilot study that explores the feasibility and efficacy of combinatorial non-viral gene delivery system for bone regeneration appears to provide a rationale for investigation of sequential delivery of growth factors at specific time points during the healing phases and this will be explored further in future studies.
Export Options
About this article
Cite this article as:
R. D'Mello Sheetal, Elangovan Satheesh, Hong Liu, D. Ross Ryan, Sumner D. Rick and K. Salem Aliasger, A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects, Current Pharmaceutical Biotechnology 2015; 16 (7) . https://dx.doi.org/10.2174/138920101607150427112753
DOI https://dx.doi.org/10.2174/138920101607150427112753 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results
Current Radiopharmaceuticals Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Gene Clusters, Molecular Evolution and Disease: A Speculation
Current Genomics Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Clinical Development of Palbociclib: An Overview
Medicinal Chemistry Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Recent Advances in Understanding of Kinetic Interplay Between Phase II Metabolism and Efflux Transport
Current Drug Metabolism Meet Our Editorial Board Member:
Current Drug Metabolism Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry The Pim Kinases: New Targets for Drug Development
Current Drug Targets Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy